BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

630 related articles for article (PubMed ID: 28751463)

  • 1. Dual Src Kinase/Pretubulin Inhibitor KX-01, Sensitizes ERα-negative Breast Cancers to Tamoxifen through ERα Reexpression.
    Anbalagan M; Sheng M; Fleischer B; Zhang Y; Gao Y; Hoang V; Matossian M; Burks HE; Burow ME; Collins-Burow BM; Hangauer D; Rowan BG
    Mol Cancer Res; 2017 Nov; 15(11):1491-1502. PubMed ID: 28751463
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Peptidomimetic Src/pretubulin inhibitor KX-01 alone and in combination with paclitaxel suppresses growth, metastasis in human ER/PR/HER2-negative tumor xenografts.
    Anbalagan M; Ali A; Jones RK; Marsden CG; Sheng M; Carrier L; Bu Y; Hangauer D; Rowan BG
    Mol Cancer Ther; 2012 Sep; 11(9):1936-47. PubMed ID: 22784709
    [TBL] [Abstract][Full Text] [Related]  

  • 3. KX-01, a novel Src kinase inhibitor directed toward the peptide substrate site, synergizes with tamoxifen in estrogen receptor α positive breast cancer.
    Anbalagan M; Carrier L; Glodowski S; Hangauer D; Shan B; Rowan BG
    Breast Cancer Res Treat; 2012 Apr; 132(2):391-409. PubMed ID: 21509526
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antitumor Effect of KX-01 through Inhibiting Src Family Kinases and Mitosis.
    Kim S; Min A; Lee KH; Yang Y; Kim TY; Lim JM; Park SJ; Nam HJ; Kim JE; Song SH; Han SW; Oh DY; Kim JH; Kim TY; Hangauer D; Lau JY; Im K; Lee DS; Bang YJ; Im SA
    Cancer Res Treat; 2017 Jul; 49(3):643-655. PubMed ID: 27737538
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Arsenic trioxide restores ERα expression in ERα-negative human breast cancer cells and its treatment efficacy in combination with tamoxifen in xenografts in nude mice].
    Zhang WJ; Xu DF; Fan QX; Wu XA; Wang F; Wang R; Wang LX
    Zhonghua Zhong Liu Za Zhi; 2012 Sep; 34(9):645-51. PubMed ID: 23159075
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reactivation of estrogen receptor α by vorinostat sensitizes mesenchymal-like triple-negative breast cancer to aminoflavone, a ligand of the aryl hydrocarbon receptor.
    Stark K; Burger A; Wu J; Shelton P; Polin L; Li J
    PLoS One; 2013; 8(9):e74525. PubMed ID: 24058584
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epigenetic reactivation of estrogen receptor-α (ERα) by genistein enhances hormonal therapy sensitivity in ERα-negative breast cancer.
    Li Y; Meeran SM; Patel SN; Chen H; Hardy TM; Tollefsbol TO
    Mol Cancer; 2013 Feb; 12():9. PubMed ID: 23379261
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Arsenic trioxide re-sensitizes ERα-negative breast cancer cells to endocrine therapy by restoring ERα expression in vitro and in vivo.
    Zhang W; Wang L; Fan Q; Wu X; Wang F; Wang R; Ma Z; Yang J; Lu SH
    Oncol Rep; 2011 Sep; 26(3):621-8. PubMed ID: 21687957
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The bromodomain inhibitor OTX015 (MK-8628) exerts anti-tumor activity in triple-negative breast cancer models as single agent and in combination with everolimus.
    Vázquez R; Riveiro ME; Astorgues-Xerri L; Odore E; Rezai K; Erba E; Panini N; Rinaldi A; Kwee I; Beltrame L; Bekradda M; Cvitkovic E; Bertoni F; Frapolli R; D'Incalci M
    Oncotarget; 2017 Jan; 8(5):7598-7613. PubMed ID: 27935867
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Wnt-5a signaling restores tamoxifen sensitivity in estrogen receptor-negative breast cancer cells.
    Ford CE; Ekström EJ; Andersson T
    Proc Natl Acad Sci U S A; 2009 Mar; 106(10):3919-24. PubMed ID: 19237581
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fulvestrant inhibits growth of triple negative breast cancer and synergizes with tamoxifen in ERα positive breast cancer by up-regulation of ERβ.
    Mishra AK; Abrahamsson A; Dabrosin C
    Oncotarget; 2016 Aug; 7(35):56876-56888. PubMed ID: 27486755
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tamoxifen reverses epithelial-mesenchymal transition by demethylating miR-200c in triple-negative breast cancer cells.
    Wang Q; Cheng Y; Wang Y; Fan Y; Li C; Zhang Y; Wang Y; Dong Q; Ma Y; Teng YE; Qu X; Liu Y
    BMC Cancer; 2017 Jul; 17(1):492. PubMed ID: 28724364
    [TBL] [Abstract][Full Text] [Related]  

  • 13. FOXC1 is associated with estrogen receptor alpha and affects sensitivity of tamoxifen treatment in breast cancer.
    Wang J; Xu Y; Li L; Wang L; Yao R; Sun Q; Du G
    Cancer Med; 2017 Jan; 6(1):275-287. PubMed ID: 28028927
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anticancer effect of metformin on estrogen receptor-positive and tamoxifen-resistant breast cancer cell lines.
    Kim J; Lee J; Jang SY; Kim C; Choi Y; Kim A
    Oncol Rep; 2016 May; 35(5):2553-60. PubMed ID: 26986571
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epigenetic restoration and activation of ERβ: an inspiring approach for treatment of triple-negative breast cancer.
    Salahuddin A; Ghanem H; Omran GA; Helmy MW
    Med Oncol; 2022 Jul; 39(10):150. PubMed ID: 35843988
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sensitizing Triple Negative Breast Cancer to Tamoxifen Chemotherapy via a Redox-Responsive Vorinostat-containing Polymeric Prodrug Nanocarrier.
    Ma W; Sun J; Xu J; Luo Z; Diao D; Zhang Z; Oberly PJ; Minnigh MB; Xie W; Poloyac SM; Huang Y; Li S
    Theranostics; 2020; 10(6):2463-2478. PubMed ID: 32194813
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PAC down-regulates estrogen receptor alpha and suppresses epithelial-to-mesenchymal transition in breast cancer cells.
    Al-Howail HA; Hakami HA; Al-Otaibi B; Al-Mazrou A; Daghestani MH; Al-Jammaz I; Al-Khalaf HH; Aboussekhra A
    BMC Cancer; 2016 Jul; 16():540. PubMed ID: 27465411
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting triple-negative breast cancer cells with the histone deacetylase inhibitor panobinostat.
    Tate CR; Rhodes LV; Segar HC; Driver JL; Pounder FN; Burow ME; Collins-Burow BM
    Breast Cancer Res; 2012 May; 14(3):R79. PubMed ID: 22613095
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Transferrin Coated d-penicillamine-Au-Cu Nanocluster PLGA Nanocomposite Reverses Hypoxia-Induced EMT and MDR of Triple-Negative Breast Cancers.
    Shome R; Ghosh SS
    ACS Appl Bio Mater; 2021 Jun; 4(6):5033-5048. PubMed ID: 35007052
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Radiosensitization with combined use of olaparib and PI-103 in triple-negative breast cancer.
    Jang NY; Kim DH; Cho BJ; Choi EJ; Lee JS; Wu HG; Chie EK; Kim IA
    BMC Cancer; 2015 Mar; 15():89. PubMed ID: 25884663
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.